Continuously improving TIL testing quality to build a more comprehensive tumor immunology analysis.

‍

Tumor-Infiltrating Lymphocytes (TILs) are a cornerstone of tumor immunology research and cell therapy. Because immune cell composition, the tumor microenvironment, and levels of immunosuppression vary significantly between patients, establishing a standardized, high-quality TIL testing workflow is a vital step toward precision medicine.

Axiom Biotech is continuously optimizing its TIL testing workflow by integrating multi-color flow cytometry, AI Cell Report, and immune cell analysis technologies, with the goal of building a more comprehensive and consistent tumor immunology assessment platform.